|
TARS | Tarsus Pharmaceuticals, Inc. |
|
|
TARS | Tarsus Pharmaceuticals, Inc. |
| Biological Products (no Diagnostic Substances) |
| Book value per $ invested | $ 0.48 |
| Leverage | 39.27% |
| Market Cap | $ 2.2B |
| PE | 0.00 |
| Dividend Yield | 0.00% |
| Profit | $ -48.2m |
| Margin | -9.03% |
Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of new therapeutic candidates for ophthalmic conditions. The company is headquartered in Irvine, California.